Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy

NCT01737450 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT01737450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01737450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
March 31, 2019
Enrollment
58 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck neoplasms, neoplasm metastasis, progressive disease, recurrent disease